Detection of relevant pharmacogenetic information through exome sequencing in oncology

References

• 1. Pirmohamed M, Park BK. Genetic susceptibility to adverse drug reactions. Trends Pharmacol. Sci. 22(6), 298–305 (2001).
  Medline CASGoogle Scholar
• 2. Relling MV, Klein TE, Gammal RS, Whirl‐Carrillo M, Hoffman JM, Caudle KE. The Clinical Pharmacogenetics Implementation Consortium: 10 years later. Clin. Pharmacol. Ther. 107(1), 171–175 (2020).
  MedlineGoogle Scholar
• 3. Matic M, Nijenhuis M, Soree B et al. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone). Eur. J. Hum. Genet. doi: s41431-021-00920-y (2021) (Epub ahead of print).
  Google Scholar
• 4. Picard N, Boyer J-C, Etienne-Grimaldi M-C, Barin-Le Guellec C, Thomas F, Loriot M-A. Pharmacogenetics-based personalized therapy: levels of evidence and recommendations from the French Network of Pharmacogenetics (RNPGx). Therapies 72(2), 185–192 (2017).
  MedlineGoogle Scholar
• 5. Whirl-Carrillo M, McDonagh EM, Hebert JM et al. Pharmacogenomics knowledge for personalized medicine. Clin. Pharmacol. Ther. 92(4), 414–417 (2012).
  Medline CASGoogle Scholar
• 6. Ansfield FJ. Five years clinical experience with 5-fluorouracil. JAMA 181(4), 295 (1962).
  Medline CASGoogle Scholar
• 7. Meta-Analysis Group in Cancer, Lévy E, Piedbois P et al. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J. Clin. Oncol. 16(11), 3537–3541 (1998).
  MedlineGoogle Scholar
• 8. Amstutz U, Henricks LM, Offer SM et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin. Pharmacol. Ther. 103(2), 210–216 (2018).
  Medline CASGoogle Scholar
• 9. Van Kuilenburg ABP, Van Lenthe H, Tromp A, Veltman PCJ, Van Gennip AH. Pitfalls in the diagnosis of patients with a partial dihydropyrimidine dehydrogenase deficiency. Clin. Chem. 46(1), 9–17 (2000).
  Medline CASGoogle Scholar
• 10. Etienne MC, Lagrange JL, Dassonville O et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. JCO 12(11), 2248–2253 (1994).
  Medline CASGoogle Scholar
• 11. Loriot M-A, Ciccolini J, Thomas F et al. Dépistage du déficit en dihydropyrimidine déshydrogénase (DPD) et sécurisation des chimiothérapies à base de fluoropyrimidines: mise au point et recommandations nationales du GPCO-Unicancer et du RNPGx. Bull. Cancer 105(4), 397–407 (2018).
  MedlineGoogle Scholar
• 12. Thomas F, Hennebelle I, Delmas C et al. Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio. Clin. Pharmacol. Ther. 99(2), 235–242 (2016).
  Medline CASGoogle Scholar
• 13. Ciccolini J, Mercier C, Evrard A et al. A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy. Ther. Drug Monit. 28(5), 678–685 (2006).
  Medline CASGoogle Scholar
• 14. Meulendijks D, Henricks LM, Jacobs BAW et al. Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity. Br. J. Cancer 116(11), 1415–1424 (2017).
  Medline CASGoogle Scholar
• 15. van Staveren MC, van Kuilenburg ABP, Guchelaar H-J et al. Evaluation of an oral uracil loading test to identify DPD-deficient patients using a limited sampling strategy: uracil loading dose to detect DPD deficiency. Br. J. Clin. Pharmacol. 81(3), 553–561 (2016).
  Medline CASGoogle Scholar
• 16. Bocci G, Barbara C, Vannozzi F et al. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. Clin. Pharmacol. Ther. 80(4), 384–395 (2006).
  Medline CASGoogle Scholar
• 17. Henricks LM, Lunenburg CATC, de Man FM et al. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol. 19(11), 1459–1467 (2018)
  Medline CASGoogle Scholar
• 18. Gaedigk A. Complexities of CYP2D6 gene analysis and interpretation. Int. Rev. Psychiatry 25(5), 534–553 (2013)
  MedlineGoogle Scholar
• 19. Nofziger C, Turner AJ, Sangkuhl K et al. PharmVar GeneFocus: CYP2D6. Clin. Pharmacol. Ther. 107(1), 154–170 (2020).
  Medline CASGoogle Scholar
• 20. Taylor C, Crosby I, Yip V, Maguire P, Pirmohamed M, Turner RM. A review of the important role of CYP2D6 in pharmacogenomics. Genes 11(11), 1295 (2020).
  CASGoogle Scholar
• 21. Gasche Y, Daali Y, Fathi M et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N. Engl. J. Med. 351(27), 2827–2831 (2004).
  Medline CASGoogle Scholar
• 22. Zwisler ST, Enggaard TP, Noehr-Jensen L et al. The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism. Basic Clin. Pharmacol. Toxicol. 104(4), 335–344 (2009).
  Medline CASGoogle Scholar
• 23. Crews KR, Gaedigk A, Dunnenberger HM et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin. Pharmacol. Ther. 95(4), 376–382 (2014).
  Medline CASGoogle Scholar
• 24. Stamer UM, Lee E-H, Rauers NI et al. CYP2D6- and CYP3A-dependent enantioselective plasma concentrations of ondansetron in postanesthesia care: anesthesia & analgesia. 113(1), 48–54 (2011).
  Google Scholar
• 25. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472), 1687–1717 (2005).
  MedlineGoogle Scholar
• 26. Buck MB, Coller JK, Mürdter TE, Eichelbaum M, Knabbe C. TGFβ2 and TβRII are valid molecular biomarkers for the antiproliferative effects of tamoxifen and tamoxifen metabolites in breast cancer cells. Breast Cancer Res. Treat. 107(1), 15–24 (2007).
  MedlineGoogle Scholar
• 27. Schroth W, Winter S, Mürdter T et al. Improved prediction of endoxifen metabolism by CYP2D6 genotype in breast cancer patients treated with tamoxifen. Front. Pharmacol. 8, 582 (2017).
  MedlineGoogle Scholar
• 28. Hertz DL, McLeod HL, Irvin WJ. Tamoxifen and CYP2D6: a contradiction of data. Oncologist 17(5), 620–630 (2012)
  Medline CASGoogle Scholar
• 29. Réda M, Richard C, Bertaut A et al. Implementation and use of whole exome sequencing for metastatic solid cancer. EBioMedicine 51, 102624 (2020).
  MedlineGoogle Scholar
• 30. Bruel A-L, Nambot S, Quéré V et al. Increased diagnostic and new genes identification outcome using research reanalysis of singleton exome sequencing. Eur. J. Hum. Genet. 27(10), 1519–1531 (2019).
  Medline CASGoogle Scholar
• 31. Thevenon J, Duffourd Y, Masurel-Paulet A et al. Diagnostic odyssey in severe neurodevelopmental disorders: toward clinical whole-exome sequencing as a first-line diagnostic test. Clin. Genet. 89(6), 700–707 (2016).
  Medline CASGoogle Scholar
• 32. Cingolani P, Patel VM, Coon M et al. Using Drosophila melanogaster as a model for genotoxic chemical mutational studies with a new program, SnpSift. Front. Gene 3, 35 (2012).
  MedlineGoogle Scholar
• 33. Lee S, Wheeler MM, Patterson K et al. Stargazer: a software tool for calling star alleles from next-generation sequencing data using CYP2D6 as a model. Genet. Med. 21(2), 361–372 (2019).
  Medline CASGoogle Scholar
• 34. Sherry ST. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 29(1), 308–311 (2001).
  Medline CASGoogle Scholar
• 35. Macaire P, Morawska K, Vincent J et al. Therapeutic drug monitoring as a tool to optimize 5-FU–based chemotherapy in gastrointestinal cancer patients older than 75 years. Eur. J. Cancer 111, 116–125 (2019).
  Medline CASGoogle Scholar
• 36. Caspar SM, Schneider T, Stoll P, Meienberg J, Matyas G. Potential of whole-genome sequencing-based pharmacogenetic profiling. Pharmacogenomics 22(3), 177–190 (2021).
  CASGoogle Scholar
• 37. Henricks LM, Lunenburg CATC, de Man FM et al. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol. 19(11), 1459–1467 (2018).
  Medline CASGoogle Scholar
• 38. Vreken P, Kuilenburg ABPV, Meinsma R, van Gennip AH. Dihydropyrimidine dehydrogenase (DPD) deficiency: identification and expression of missense mutations C29R, R886H and R235W. Hum. Genet. 101(3), 333–338 (1997).
  Medline CASGoogle Scholar
• 39. Ezzeldin HH, Lee AM, Mattison LK, Diasio RB. Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. Clin. Cancer Res. 11(24), 8699–8705 (2005).
  Medline CASGoogle Scholar
• 40. Pellicer M, García-González X, García MI et al. Identification of new SNPs associated with severe toxicity to capecitabine. Pharmacol. Res. 120, 133–137 (2017).
  Medline CASGoogle Scholar
• 41. Stamer UM, Musshoff F, Kobilay M, Madea B, Hoeft A, Stuber F. Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes. Clin. Pharmacol. Ther. 82(1), 41–47 (2007).
  Medline CASGoogle Scholar
• 42. Smith DM, Weitzel KW, Elsey AR et al. CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial. Genet. Med. 21(8), 1842–1850 (2019).
  Medline CASGoogle Scholar
• 43. de Leon J, Dinsmore L, Wedlund P. Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers. J. Clin. Psychopharmacol. 23(4), 420–421 (2003).
  MedlineGoogle Scholar
• 44. Gasche Y, Daali Y, Fathi M et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N. Engl. J. Med. 351(27), 2827–2831 (2004).
  Medline CASGoogle Scholar
• 45. Dalén P, Frengell C, Dahl M-L, Sjöqvist F. Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine. Ther. Drug Monit. 19(5), 543–544 (1997).
  Medline CASGoogle Scholar
• 46. Dagostino C, Allegri M, Napolioni V et al. CYP2D6 genotype can help to predict effectiveness and safety during opioid treatment for chronic low back pain: results from a retrospective study in an Italian cohort. PGPM 11, 179–191 (2018).
  CASGoogle Scholar
• 47. Bell G, Caudle K, Whirl-Carrillo M et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron. Clin. Pharmacol. Ther. 102(2), 213–218 (2017).
  Medline CASGoogle Scholar
• 48. Candiotti KA, Birnbach DJ, Lubarsky DA et al. The impact of pharmacogenomics on postoperative nausea and vomiting. Anesthesiology 102(3), 543–549 (2005).
  Medline CASGoogle Scholar
• 49. Wu X, Hawse JR, Subramaniam M, Goetz MP, Ingle JN, Spelsberg TC. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor α for degradation in breast cancer cells. Cancer Res. 69(5), 1722–1727 (2009).
  Medline CASGoogle Scholar
• 50. Chang M-S. Tamoxifen resistance in breast cancer. Biomol. Ther. (Seoul) 20(3), 256–267 (2012).
  Medline CASGoogle Scholar
• 51. Neven P, Jongen L, Lintermans A et al. Tamoxifen metabolism and efficacy in breast cancer: a prospective multicenter trial. Clin. Cancer Res. 24(10), 2312–2318 (2018).
  Medline CASGoogle Scholar
• 52. Sanchez-Spitman A, Dezentjé V, Swen J et al. Tamoxifen pharmacogenetics and metabolism: results from the prospective CYPTAM study. JCO 37(8), 636–646 (2019).
  Medline CASGoogle Scholar
• 53. Goetz MP, Sangkuhl K, Guchelaar H-J et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and tamoxifen therapy. Clin. Pharmacol. Ther. 103(5), 770–777 (2018).
  MedlineGoogle Scholar
• 54. Xue Y, Ankala A, Wilcox WR, Hegde MR. Solving the molecular diagnostic testing conundrum for Mendelian disorders in the era of next-generation sequencing: single-gene, gene panel, or exome/genome sequencing. Genet. Med. 17(6), 444–451 (2015).
  Medline CASGoogle Scholar